Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020)
Forte Biosciences (FBRX) reported Non Operating Investment Income of -$10000.0 for Q1 2020, down 124.39% year-over-year from $41000.0 in Q2 2019, and up 69.7% quarter-over-quarter from -$33000.0 in Q4 2019.
Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has 5 years of Non Operating Investment Income data on file, last reported at -$10000.0 in Q1 2020.
- Non Operating Investment Income for Q1 2020 came in at -$10000.0, down 124.39% year-over-year; the trailing twelve-month figure through Mar 2020 was -$18000.0 (down 114.29% YoY), and the FY2019 annual result was $33000.0, up 200.0% from the prior year.
- Non Operating Investment Income climbed to -$10000.0 in Q1 2020 per FBRX's latest filing, from -$33000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $54000.0 in Q1 2016 and troughed at -$74000.0 in Q1 2018.
- A 5-year average of $3866.7 and a median of -$1000.0 in 2017 frame the typical range for Non Operating Investment Income.
- On a YoY basis, Non Operating Investment Income climbed as much as 1000.0% in 2018 and fell as far as 7300.0% in 2018.
- A 5-year view of Non Operating Investment Income shows it stood at -$9000.0 in 2016, then tumbled by 244.44% to -$31000.0 in 2017, then jumped by 200.0% to $31000.0 in 2018, then slumped by 206.45% to -$33000.0 in 2019, then soared by 69.7% to -$10000.0 in 2020.
- Business Quant data shows FBRX's Non Operating Investment Income at -$10000.0 in Q1 2020, -$33000.0 in Q4 2019, and -$13000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -10,000.00 |
| Mar 31, 2020 | -10,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Mar 31, 2018 | -74,000.00 |
| Mar 31, 2018 | -74,000.00 |
| Dec 31, 2017 | -31,000.00 |
| Dec 31, 2017 | -31,000.00 |
| Sep 30, 2017 | 4,000.00 |
| Sep 30, 2017 | 4,000.00 |